Tilray's Record Revenue Story Comes With a Cash-Burn Caveat
Published on 08/05/2026 at 16:44 | Redaktion boerse-global.de
The headline numbers from Tilray Brands' fiscal 2026 results were the kind that typically sends a cannabis stock running. Revenue hit an all-time high of $915.5 million, the net loss narrowed to $105.2 million, and management is talking about crossing the billion-dollar sales threshold in the year ahead. Investors responded by pushing shares up roughly 3 percent on the Toronto Stock Exchange to C$6.53 on Tuesday, extending the week's gain to nearly 17.9 percent. The stock also traded at $4.64 on the Nasdaq.
But peel back the top line and a more complicated picture emerges — one that has analysts divided and raises legitimate questions about how much of this growth is actually sustainable.
The Growth Engine Has Two Speeds
Tilray's revenue climbed 11 percent year over year, driven by its cannabis and beverage segments. The beverage business, in particular, posted a 19 percent growth rate with $241 million in sales. Yet a Motley Fool analysis points out that much of that expansion came from acquisitions rather than organic momentum. The company's diversification push — which now spans beer, wellness products, and hospitality — has made Tilray look like a broadly based consumer company from a distance, but the underlying organic growth rate tells a different story.
That acquisitive strategy has a cost beyond the purchase price. Tilray continues to fund growth through share issuance, and the dilution is becoming harder to ignore. The weighted average share count jumped 26 percent during fiscal 2026 to 111.8 million shares, with the fourth quarter alone seeing an 18 percent increase to 115.5 million. The company raised $158.0 million through equity sales after costs, and an at-the-market program launched in April allows for additional sales of up to $180 million. Through July 28, Tilray had already generated $87 million in gross proceeds from that program at an average price of $6.77 per share.
Where the Cash Actually Goes
The gap between adjusted and GAAP figures is where the strain shows. Tilray reported adjusted EBITDA of $61.1 million and an adjusted net profit of $12.2 million — numbers that suggest a business approaching profitability. But under GAAP accounting, the company posted a net loss of $105.2 million, and the cash flow statement is arguably more concerning. Operating cash flow came in at negative $69.1 million over the past twelve months, while investing activities — including acquisitions — consumed another $56 million. Free cash flow landed at negative $98.6 million.
The balance sheet offers some cushion. As of the end of May, Tilray held roughly $235 million in cash, restricted funds, and securities. Net debt stood at a modest $0.7 million, though total liabilities of about $227 million and lease obligations of $171.5 million mean the company is far from debt-free.
Wall Street Can't Quite Agree
The analyst community has responded to the results with a notable lack of consensus. TD Cowen's Derek Lessard reiterated a Buy rating with a $5 price target, while the firm separately trimmed its target from $7 to $5. Jefferies has expressed confidence in the long-term value of Tilray's diversification strategy. On the more cautious side, ATB's Frederico Gomes and Alliance Global's Aaron Grey both maintain Hold ratings with price targets of $8 and $5, respectively.
Management, for its part, is looking ahead with confidence. For fiscal 2027, Tilray guides to adjusted EBITDA between $68 million and $75 million — an 11 to 23 percent improvement — and expects revenue to exceed $1 billion. CEO Irwin Simon has framed the next chapter as one that won't be defined by any single product, market, or regulatory ruling.
Insider Buying Adds a Signal
Amid the mixed analyst sentiment, executives have been putting their own money to work. CFO Carl A. Merton purchased 10,000 shares at $4.62 each on Tuesday through the open market, bringing his direct holdings to 139,753 shares. The prior day, Chief Strategy Officer Denise M. Faltischek bought 2,500 shares at $4.78, raising her stake to 141,285 shares. Both transactions occurred outside automated trading plans — a gesture that some market observers read as a confidence signal from leadership, even in a sector known for volatility.
While market signals can be hard to read, workplace safety obligations are clearer — and getting them wrong carries real financial risk. Many UK employers unknowingly miss compliance gaps that inspectors actively look for. A free toolkit with 41 ready-to-use checklists and templates helps you document hazards properly and stay on the right side of the law. Download the free Risk Assessment Toolkit
There's also a side note that underscores how far Tilray has branched beyond cannabis: BrewDog, the British brewer acquired this year, is facing scrutiny from privacy regulators over an email campaign by founder James Watt. Watt is reportedly exploring a buyback of the brand using 43,000 "Equity Punks" — small investors from an earlier crowdfunding round. It's a minor storyline for Tilray shareholders, but it illustrates the breadth of the company's portfolio.
With a market capitalization of roughly €532.27 million, Tilray remains a small-cap whose valuation hinges on its growth narrative. The central tension for investors is straightforward: can the revenue momentum justify continued share dilution while operating cash flow remains negative? The insider purchases and the stock's recent run suggest some conviction, but the cash burn and the widening gap between adjusted and reported earnings keep the risk firmly in view.
